ClinicalTrials.gg
CompletedNCT00932763Updated Jul 17, 2009

Study to Evaluate the Bioavailability of the Test Formulation of Amlodipine 10 mg Tablets (Torrent Pharmaceuticals Limited) Compared to a 10 mg Dose of Norvasc® (Pfizer) in 22 Fasted, Healthy Adult Subjects

A Phase 1 interventional study of Amlodipine besylate and Norvasc in Healthy, sponsored by Torrent Pharmaceuticals Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2009-07-17.

Sponsored by Torrent Pharmaceuticals Limited · Phase 1 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Ages
18 Years to 45 Years
Sex
All
01

Study summary

  • Objective:

    • The objective of this study was to assess the relative bioavailability of two formulations of immediate release amlodipine 10 mg under fasted conditions, in healthy subjects.
  • Study Design:

    • This was an open-label, single-dose, 2-treatment, 2-period, randomized, crossover study.Twenty-two healthy subjects were enrolled. Subjects who successfully completed the screening process checked into the research center the night before first dose. Subjects who continued to meet inclusion/exclusion criteria the morning of dose were assigned a subject number, based on the order in which they successfully completed the screening process and procedures as outlined in the study protocol. Subjects were randomly assigned to a treatment sequence and received two separate single-dose administrations of study medication, one treatment per period,according to the randomization schedule. Dosing days were separated by a washout period of at least 14 days. Subjects received each of the treatments listed below during the two treatment periods following an overnight fast of at least 10 hours: amlodipine by Torrent Pharmaceuticals Ltd. and Norvasc by Pfizer, Inc.
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Torrent Pharmaceuticals Limited is the lead sponsor of 72 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sex: Male/Female
  • Age: 18 - 45 years.
  • Volunteer with of 18-27 kg/m2 with minimum of 50 kg weight.
  • Volunteers with minimum blood pressure of 110/75 mmHg.
  • Healthy and willing to participate in the study.
  • Signed Written for Screening and study.
  • Medical case history, physical examination, vital signs, laboratory tests and without significant deviations.
  • Negative drug of abuse screening test.
  • Non-smokers or smoking less than 10 cigarettes a day and willing to refrain from smoking throughout the course of the study.
  • No history of medication, prescription or OTC, for at least 2 weeks prior to study drug administration until study Period II completion.

Exclusion criteria

Exclusion Criteria:

  • abnormal physical findings at the screening examination, which would interfere with the objective of the study.
  • Clinically relevant abnormalities in the results of the laboratory screening evaluation.
  • Clinically relevant abnormalities.
  • Habituation of tobacco necessitating uninterrupted tobacco consumption.
  • Addiction to alcohol or history of any drug abuse.
  • History of kidney or liver dysfunction.
  • History of allergy to the test drug or any drug chemically similar to the drug under investigation.
  • Administration/Intake of any prescription or OTC medication for two weeks before the study.
  • Patients suffering from any chronic illness such as arthritis, asthma etc.
  • , , positive volunteers.
  • Positive test for drugs of abuse screen.
  • Subjects suffering from any psychiatric (acute or chronic) illness.
  • Administration of any drug in the period 0 to 30 days before entry into the study.
  • Intake of barbiturates or any enzyme-inducing drug in last three months.
  • History of significant blood loss due to any reason, including blood donation in the past 12 weeks. The total blood loss in last 3 months including anticipated blood loss for this study will exceed 1000 ml.
  • History of any bleeding disorder.
  • Existence of any surgical or medical condition, which, in the judgement of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers.
  • Serious adverse reaction or to study drug or any of the .
  • Inability to communicate or cooperate with the investigator due to language problem, poor mental development or impaired cerebral function.
  • Pregnant and nursing mother.
  • Female, unless surgically sterile or at least 2 years , not practicing barrier methods.
  • to active or inactive ingredients of the formulation.
  • Subject is not willing and able to remain in the study unit for the entire duration of each confinement period and return for all outpatient visits.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence

07

Study locations

1 site
  • CEDRA Clinical Research, LLC
    San Antonio, Texas 78217, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00932763
First posted
Jul 3, 2009
Last update
Jul 17, 2009
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion